ETI-311

ETI-311 is a chimeric monoclonal antibody developed by Elusys Therapeutics for the treatment and prophylaxis of anthrax, a life-threatening infection caused by *Bacillus anthracis*. The antibody is designed to bind with high affinity to the protective antigen (PA) component of the anthrax toxin complex. By binding to PA, ETI-311 prevents the assembly of the lethal toxin and edema toxin complexes and blocks their entry into host cells, thereby neutralizing the primary virulence factors of the bacteria. ETI-311 underwent early-stage clinical evaluation, including a Phase 1 trial to assess safety and pharmacokinetics in healthy volunteers. However, development of this specific chimeric version was superseded by ETI-204 (obiltoxaximab), a de-immunized version of the same antibody designed to reduce potential immunogenicity for long-term use and repeated administration in humans.

Other names

chimeric 14B7chimeric14B7chimeric-14B7